Company Description
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis.
The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025.
BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
| Country | Switzerland |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12,000 |
| CEO | John Oyler |
Contact Details
Address: 94 Aeschengraben 27 Basel, 4051 Switzerland | |
| Phone | 41 61 685 19 00 |
| Website | beonemedicines.com |
Stock Details
| Ticker Symbol | ONC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651308 |
| ISIN Number | US07725L1026 |
| Employer ID | 98-1209416 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John V. Oyler | Co-Founder, Executive Chairman and Chief Executive Officer |
| Wang Lai Ph.D. | President and Global Head of Research and Development |
| Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board, Non-Executive Director and Co-Founder |
| Aaron Rosenberg | Chief Financial Officer |
| Chan Lee | General Counsel, Senior Vice President and Corporate Secretary |
| Titus B. Ball | Vice President and Chief Accounting Officer |
| Marcello Damiani | Chief Technology Officer |
| Liza Heapes | Head of Investor Relations |
| Eleanor Duff Ph.D. | Senior Vice President and Head of Corporate Communications |
| Dr. Mark Lanasa | Senior Vice President and Chief Medical Officer for Solid Tumors |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | 8-K | Current Report |
| May 14, 2026 | SCHEDULE 13G/A | Filing |
| May 13, 2026 | 144 | Filing |
| May 6, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| May 6, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| May 6, 2026 | 10-Q | Quarterly Report |
| May 6, 2026 | 8-K | Current Report |
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |